中国医药创新促进会资深会长宋瑞霖：让中国不只是医药创新的“种子提供者”

Group 1 - The core viewpoint is that China is transitioning from a "license in" model to a "license out" model in the pharmaceutical industry, becoming a significant source of global pharmaceutical innovation [2] - The Chinese pharmaceutical market is evolving from being a passive recipient of technology to an active exporter of innovation, with a call for improvements in clinical research and payment mechanisms [2] - There are structural shortcomings in key areas such as clinical research and technology transfer, with less than 5% of domestic medical institutions achieving significant technology transfer revenue [2] Group 2 - Establishing a domestic innovative drug market in China is crucial, with suggestions to explore paths like an "innovative drug catalog" to balance healthcare funding pressures and encourage innovation [3] - The development of a robust commercial health insurance system is seen as beneficial for enhancing the market competitiveness of Chinese innovative drugs, as social security alone cannot bear the high costs of innovative drugs [3] - A more vibrant, open, and flexible domestic market could provide China with the opportunity to nurture multinational pharmaceutical companies [3]